Blood-based Gene Expression Signatures in Lung Cancer

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides a method for diagnosing or detecting lung cancer in humans using gene expression analysis from blood samples. It identifies 361 genes with different expression patterns in lung cancer patients and establishes that measuring at least four specific mRNAs from blood can accurately indicate the presence of lung cancer.

Use CasesContent extracted from patent full text and abstract with AI.

• Early detection of lung cancer in routine health screenings
• Non-invasive diagnostic tests for individuals at risk of lung cancer
• Monitoring lung cancer progression or response to treatment
• Developing personalized treatment plans based on gene expression profiles

BenefitsContent extracted from patent full text and abstract with AI.

• Minimally invasive diagnosis through a simple blood test
• Higher accuracy (AUC ≥ 0.8) compared to some existing methods
• Potential for early detection, improving treatment outcomes
• Reduces the need for more invasive diagnostic procedures like biopsies

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention pertains to a method for diagnosing or detecting lung cancer in human subjects based on ribonucleic acid (RNA) expression, in particular based on RNA from blood. The invention discloses 361 genes which are differentially expressed in blood from lung cancer patients and discloses that at least 4 of the mRNAs must be determined in order to have an AUC of at least 0.8.